Gregory W. Albers, MD

Experts weigh factor XIa inhibitor asundexian after ischemic stroke, highlighting strong efficacy and safety signals and fueling optimism for Librexia Stroke trial results.

Global trial tests ascendexian after ischemic stroke/TIA, showing low bleeding and raising questions about diversity and real-world fit.

Global trial tests ascendexian after ischemic stroke/TIA, showing low bleeding and raising questions about diversity and real-world fit.

Experts unpack a global stroke-prevention trial, weighing real-world fit, diversity gaps, reperfusion patients, and surprisingly low bleeding.

Experts explain how factor XIa inhibitors may prevent post‑stroke clots while sparing hemostasis, offering safer anticoagulation ahead of Phase III.

Experts explain why lowering blood pressure below 130/80 cuts stroke risk, and share practical tips on adherence, apps, and polypill therapy.

New stroke-prevention guidance urges early dual antiplatelets for minor stroke/TIA, faster anticoagulation for AF, and LDL targets plus diet focus.

Clinicians tailor secondary stroke prevention talks by cause, literacy, and resources—boosting adherence through risk-factor coaching, shared decisions, and affordable antithrombotics.

Clinicians explain secondary stroke prevention by tailoring education, addressing risk factors, and choosing affordable antithrombotic plans through shared decision-making to boost adherence.

Stroke recurrence risk peaks in the first days after TIA or minor stroke, driving rapid evaluation and tailored prevention strategies like short-term dual antiplatelet therapy.

Experts unpack stroke recurrence disparities, AHA prevention tactics, lifestyle essentials, and emerging factor XIa inhibitors shaping future care.

Panelists share tailored stroke recurrence prevention: control BP, lipids, and lifestyle, address disparities, and weigh factor XIa inhibitors.

The professor of neurology and director of the Stanford Stroke Center discussed the ways stroke care is evolving and the significance of the TIMELESS trial, which demonstrated the safety of tenecteplase in later-window poststroke patients. [WATCH TIME: 7 minutes]

The professor of neurology and director of the Stanford Stroke Center provided commentary on clinical implications of findings from the TIMELESS trial assessing tenecteplase initiated in the late window after stroke onset. [WATCH TIME: 4 minutes]

The director of the Stanford Stroke Center and Coyote Foundation Professor of Neurology and Neurological Sciences at Stanford Medical Center shared his perspective on the uptake of mobile stroke units across the United States. [WATCH TIME: 6 minutes]